-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Aadi Bioscience, Inc. (NASDAQ:AADI) Position Raised by Point72 Asset Management L.P.
Aadi Bioscience, Inc. (NASDAQ:AADI) Position Raised by Point72 Asset Management L.P.
Point72 Asset Management L.P. increased its position in shares of Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) by 156.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 542,044 shares of the company's stock after purchasing an additional 330,513 shares during the period. Point72 Asset Management L.P. owned 2.59% of Aadi Bioscience worth $6,678,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in AADI. Qube Research & Technologies Ltd acquired a new position in Aadi Bioscience in the first quarter worth approximately $294,000. Decheng Capital Management III Cayman LLC acquired a new position in Aadi Bioscience in the first quarter worth approximately $8,932,000. Renaissance Technologies LLC grew its position in Aadi Bioscience by 8.6% in the first quarter. Renaissance Technologies LLC now owns 139,522 shares of the company's stock worth $2,368,000 after buying an additional 11,000 shares during the last quarter. UBS Group AG grew its position in Aadi Bioscience by 135.3% in the first quarter. UBS Group AG now owns 56,684 shares of the company's stock worth $961,000 after buying an additional 32,590 shares during the last quarter. Finally, Eversept Partners LP acquired a new position in Aadi Bioscience in the first quarter worth approximately $2,559,000. Institutional investors and hedge funds own 63.00% of the company's stock.
Get Aadi Bioscience alerts:Aadi Bioscience Stock Performance
AADI stock opened at $13.26 on Friday. The firm has a 50 day simple moving average of $13.18 and a 200 day simple moving average of $13.32. Aadi Bioscience, Inc. has a 52 week low of $11.00 and a 52 week high of $26.60. The stock has a market cap of $323.54 million, a P/E ratio of -4.45 and a beta of 1.28.
Aadi Bioscience (NASDAQ:AADI – Get Rating) last released its earnings results on Wednesday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.07. Aadi Bioscience had a negative net margin of 569.57% and a negative return on equity of 44.28%. The company had revenue of $4.25 million during the quarter, compared to the consensus estimate of $3.60 million. Sell-side analysts predict that Aadi Bioscience, Inc. will post -2.86 EPS for the current year.Wall Street Analyst Weigh In
Separately, LADENBURG THALM/SH SH cut their target price on shares of Aadi Bioscience to $47.00 in a research note on Tuesday, November 15th.
About Aadi Bioscience
(Get Rating)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.
Featured Stories
- Get a free copy of the StockNews.com research report on Aadi Bioscience (AADI)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
Point72 Asset Management L.P. increased its position in shares of Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) by 156.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 542,044 shares of the company's stock after purchasing an additional 330,513 shares during the period. Point72 Asset Management L.P. owned 2.59% of Aadi Bioscience worth $6,678,000 at the end of the most recent quarter.
根據Aadi Bioscience，Inc.(納斯達克：AADI-GET評級)在提交給美國證券交易委員會(美國證券交易委員會)的最新Form 13F檔案中顯示，Point72 Asset Management L.P.在第二季度將其在該公司股票的持倉增加了156.2。該機構投資者持有542,044股該公司股票，在此期間又購買了330,513股。截至最近一個季度末，Point72 Asset Management L.P.擁有Aadi Bioscience 2.59%的股份，價值667.8萬美元。
Several other hedge funds have also recently added to or reduced their stakes in AADI. Qube Research & Technologies Ltd acquired a new position in Aadi Bioscience in the first quarter worth approximately $294,000. Decheng Capital Management III Cayman LLC acquired a new position in Aadi Bioscience in the first quarter worth approximately $8,932,000. Renaissance Technologies LLC grew its position in Aadi Bioscience by 8.6% in the first quarter. Renaissance Technologies LLC now owns 139,522 shares of the company's stock worth $2,368,000 after buying an additional 11,000 shares during the last quarter. UBS Group AG grew its position in Aadi Bioscience by 135.3% in the first quarter. UBS Group AG now owns 56,684 shares of the company's stock worth $961,000 after buying an additional 32,590 shares during the last quarter. Finally, Eversept Partners LP acquired a new position in Aadi Bioscience in the first quarter worth approximately $2,559,000. Institutional investors and hedge funds own 63.00% of the company's stock.
其他幾家對沖基金最近也增持或減持了Aadi的股份。Qube Research&Technologies Ltd在第一季度收購了Aadi Bioscience的一個新頭寸，價值約29.4萬美元。德成資本管理III開曼有限責任公司在第一季度收購了Aadi Bioscience的一個新頭寸，價值約893.2萬美元。復興科技有限公司在第一季度將其在Aadi Bioscience的頭寸增加了8.6%。復興科技有限責任公司現在擁有139,522股該公司股票，價值2,368,000美元，在上個季度又購買了11,000股。今年第一季度，瑞銀集團在Aadi Bioscience的持倉增加了135.3%。瑞銀集團(UBS Group AG)目前持有56,684股該公司股票，價值961,000美元，上一季度又購買了32,590股。最後，Eversept Partners LP在第一季度收購了Aadi Bioscience的一個新頭寸，價值約2,559,000美元。機構投資者和對沖基金持有該公司63.00%的股票。
Aadi Bioscience Stock Performance
Aadi Bioscience股票表現
AADI stock opened at $13.26 on Friday. The firm has a 50 day simple moving average of $13.18 and a 200 day simple moving average of $13.32. Aadi Bioscience, Inc. has a 52 week low of $11.00 and a 52 week high of $26.60. The stock has a market cap of $323.54 million, a P/E ratio of -4.45 and a beta of 1.28.
上週五，Aadi股價開盤報13.26美元。該公司的50日簡單移動均線切入位在13.18美元，200日簡單移動均線切入位在13.32美元。Aadi Bioscience，Inc.的52周低點為11.00美元，52周高位為26.60美元。該股市值為3.2354億美元，本益比為-4.45，貝塔係數為1.28。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Separately, LADENBURG THALM/SH SH cut their target price on shares of Aadi Bioscience to $47.00 in a research note on Tuesday, November 15th.
另外，拉登堡THALM/SH SH在11月15日星期二的一份研究報告中將Aadi Bioscience的目標價下調至47.00美元。
About Aadi Bioscience
關於Aadi生物科學
(Get Rating)
(獲取評級)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.
Aadi Bioscience，Inc.是一家臨床階段的生物製藥公司，致力於開發和商業化mTOR途徑基因改變的基因定義癌症的精確療法。它的主要候選藥物FYARRO是一種與白蛋白結合的西羅莫司。AADI正在評估已知mTOR途徑激活的癌症的FYARRO，包括針對激活mTOR途徑的特定基因組改變的腫瘤不可知適應症。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Aadi Bioscience (AADI)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- 免費獲取StockNews.com關於Aadi生物科學的研究報告(AADI)
- MarketBeat：回顧一週12/05-12/09
- 博通有基本面價值，收益率為3.35%
- 好市多VS亞馬遜：年底攤牌
- 折扣零售商可以做好的便宜貨
- 輝瑞、強生能否繼續跑贏該指數？
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Aadi生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Aadi Bioscience和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧